LifeVantage Corp. Stock Plummets to New 52-Week Low of $6.96

LifeVantage Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.96 as of November 4, 2025. This marks a significant decline for the stock, which has underperformed the broader market, with a one-year performance of -5.66% compared to the S&P 500's gain of 19.89%.
Despite the recent downturn, LifeVantage maintains a market capitalization of USD 145 million and exhibits a price-to-earnings (P/E) ratio of 17.00. The company has a dividend yield of 1.84% and a notable return on equity (ROE) of 28.30%, indicating efficient management. However, the stock's performance has been impacted by a long-term growth rate of -5.22% in operating profit over the past five years.

In the first half of the year, LifeVantage reported a net profit of USD 5.43 million, reflecting an impressive growth of 83.16%. Additionally, the company has seen a decrease in raw material costs by 0.51% year-over-year. With institutional holdings at 55.54%, the company continues to attract significant investment interest, despite its recent challenges.